The effect of staurosporine, a potent inhibitor of protein kinases, on embryonic angiogenesis was studied in an in vivo assay system involving chorioallantoic membranes of growing chick embryo. Staurosporine inhibited embryonic angiogenesis in a dose-related manner, the ID50 value being 71 pmol/egg. Staurosporine dose-dependently suppressed the proliferation of vascular endothelial cells, an important event involved in the angiogenesis process. The IC50 value was 0.88nM. In contrast, staurosporine did not affect the migration of vascular endothelial cells.
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The effect of staurosporine, a potent inhibitor of protein kinases, on embryonic angiogenesis was studied in an in vivo assay system involving chorioallantoic membranes of growing chick embryo. Staurosporine inhibited embryonic angiogenesis in a dose-related manner, the ID50 value being 71 pmol/egg. Staurosporine dose-dependently suppressed the proliferation of vascular endothelial cells, an important event involved in the angiogenesis process. The IC50 value was 0.88nM. In contrast, staurosporine did not affect the migration of vascular endothelial cells.
These results suggest that staurosporine affected embryonic angiogenesis probably by inhibiting endothelial cell proliferation. In addition, these results might support the notion that certain protein kinase(s) could be implicated in induction of angiogenesis and also that staurosporine would be a useful compound for studying a mode of action of angiogenesis occurring in various diseases, including tumor development.
Angiogenesis occurs in normal physiological and pathophysiological conditions, such as in embryonic development, in wound healing, in diabetic retinopathy, in psoriasis and in tumor development1}. In particular, the important role of angiogenesis in the progressive growth of solid tumors is indicated by previous observations that various angiogenesis inhibitors, including angiostatic steroids, microbial products and angiostatic vitamins, have a tumor growth-inhibitory effect1~3). Angiogenesis is a result of concerted sequence of events which contains several steps, including migration and proliferation of vascular endothelial cells1 ' 2) . In addition to various growth factor peptides, several chemicals, such as prostaglandins, 1 -butyryl-glycerol and 1 2-O-tetradecanoylphorbol-1 3-acetate (TPA), cause an angiogenic response1A>5\ TPA, a potent tumor promoter, is well-known to induce its tumor promotion activity by binding to and activating protein kinase C which is a key enzyme involved in both signal transduction on cell membraneand cell proliferation6^TPAalso stimulates the growth of vascular endothelial cells and this stimulation is inhibited by staurosporine which is a potent inhibitor of protein kinases, such as protein kinase C and protein tyrosine kinase, isolated from a strain of Streptomyces7~9\ Wepreviously found that herbimycin A, a microbial inhibitor of certain protein tyrosine kinase, exhibit angiogenesisinhibitory activity in the chorioallantoic membrane (CAM)assay system10). These findings prompted us to speculate that certain protein kinase(s) might play an important role during angiogenesis. To verify this speculation, we examined the effect of staurosporine on angiogenesis in the CAM.
In this study we demonstrate that staurosporine inhibits embryonic angiogenesis in a dose-dependent manner, and also affect the proliferation of vascular endothelial cells in vitro. These results show that the antiangiogenic activity of staurosporine might involve the inhibition of certain protein kinase (s) responsible for angiogenic endothelial cell growth.
Materials and Methods

Chemicals
Staurosporine was generously supplied by Dr. T. Tamaoki Assay of Antiangiogenic Activity in CAM Antiangiogenic activity was assessed by placing an EV pellet containing a test sample on the 4.5-day-old CAM, as described previously10)ll). In brief, fertilized eggs (Ohmiya Kakin Lab., Ohmiya, Japan) were incubated in a humidified egg incubator at 37°C. After a 4.5-day incubation, an EV pellet with or without the sample examined was placed on the 4.5-day-old CAM, where embryos with chorioallantois of 3~5 mmdiameter were used in this experiment. Following additional 2-day incubation, an appropriate volume of 20%fat emulsion was injected into the chorioallantois, so that the vascular network stood out against the white background of lipid. The antiangiogenic response was evaluated by measuring the avascular zone in the CAM. The response was scored as effective whenthe avascular zone exceeded 3 mmaccording to our method10).
Vascular Endothelial Cells
Endothelial cells were prepared from bovine carotid artery and maintained in DMEM supplemented with 10%FBS, as described previously12'13*. The cells at passages 7-15 were used for subsequent experiments.
Vascular Endothelial Cell Proliferation Assay
The proliferation of endothelial cells was determined in triplicate, as described13). After endothelial cells (1 x 104 cells/well) were plated onto the wells of a 24-multiwell dishes (Falcon; Becton Dickinson Co., Lincoln, NJ) containing 1 ml of DMEM with 5% FBS and allowed to be attached to the substratum of the dish for 5hours at 37°C under an atmosphere of 5%CO2in air, various concentrations of samples (20 fA) were added into the medium and incubated in the same manner. Following incubation at 37°C for 3 days, the cells were trypsinized and then counted in a Coulter counter ZBI (Coulter Electronics Inc., Hialeah, FL).
Vascular Endothelial Cell Migration Assay
The endothelial cell migration was determined in a 48-well microchemotaxis chamber (Neuroprobe, Bethesda, MD)involving nucleopore membranefilter with 10-//m thickness and 8-//m pore size as described12). The stimulation of cell migration was induced by serum; the concentrations of FBSin the lower and upper wells were 10 and 2%, respectively. Staurosporine were added to both lower and upper wells. Cell suspensions (50^1) in 2% FBS-DMEMwere added to the wells at cell density of 2 x 104/well. After migration assays were run at 37°C for 3hours in 5%CO2 in the incubator, the cells at the upper surface of the nucleopore membrane were removed.The cells at the lower surface of the membranewere fixed in 90%ethanol and stained with hematoxyline solution, and then the total cell number was counted.
Statistical
Analysis Results as to the incidence of antiangiogenic activity were analyzed by Fisher's exact probability test with P<0.05 as the level of significance.
Results
Antiangiogenic Activity of Staurosporine
The effect of staurosporine on embryonic angiogenesis was examined by placing an EV pellet containing various doses of the agent on the surface of growing 4.5-day-old CAM. Fig. 1 shows the dose-response relationship for the appearance of an avascular zone. Staurosporine markedly inhibited embryonic angiogenesis. This potent inhibition was dose-dependent.
The minimum effective dose required for causing an avascular zone in CAM was lOng (21 pmol) per egg, when compared with the effects of empty pellets (control) which did not produce an avascular zone in any of 29CAMs tested. The ID50 value was 33 ng/egg. Representatives of these experiments are illustrated in Fig. 2 . Staurosporine produced significant avascular zone in the CAM,while an empty pellet did not exert such an effect in any of the treated CAMs. After EV pellets containing various doses of staurosporine were placed on the 4.5-day-old CAM, the antiangiogenic activity was assessed as described in Materials and Methods. The values in parentheses show the number of CAMs used. * P<0.05 compared to empty pellet-treated (i.e., control) CAMs (n=29) which did not cause antiangiogenic activity; **P<0.001 compared to the control. EVpellets with staurosporine produced an avascular zone (surrounded with arrows) showing antiangiogenic activity, while empty pellets without the agent did not. Magnification, x 2.2.
showed less effect than staurosporine, significantly inhibited angiogenesis, a value for antiangiogenic activity being 43% (3/7). There was a trend for genistein to inhibit angiogenesis, although this did not reach statistical significance; a value for antiangiogenic activity was 22% (2/9). This might be because the dose of genistein used was not sufficient to inhibit angiogenesis, that is, higher doses of genistein than that used in this study could affect angiogenesis with significant levels.
Effect of Staurosporine on Proliferation of Vascular Endothelial Cells
To determine whether or not the inhibition of angiogenesis by staurosporine was due to its inhibition of vascular endothelial cell proliferation, endothelial cells were cultured for 72hours in the presence of various concentrations of staurosporine. Staurosporine inhibited the proliferation of endothelial cell in a concentration-dependent manner. The IC50 value was 0.88 nM. To determine whether or not staurosporine affected another event in the angiogenesis process, its effect on the migration of endothelial cells was also examined. Staurosporine, at concentrations of 0.1~10nM, did not inhibit the endothelial cell migration.
Discussion
Recent studies have shown that TPA causes angiogenesis in both in vivo and in vitro assay systems5'16). TPAinduces its various biological and biochemical activities by binding to and activating protein kinase C6). Thus it is expected that an inhibitor of protein kinase C could inhibit angiogenesis, but a direct evidence for this has not yet been obtained. In this study we demonstrate that staurosporine, a potent protein kinase C inhibitor, exhibits angiogenesis-inhibitory activity. The inhibition occurred in the picomolar range. This finding suggests that protein kinase C is implicated in induction of angiogenesis. It might also imply possible involvement of other protein kinase in angiogenesis induction, because staurosporine also inhibit several protein kinases in addition to protein kinase C9). This might be supported by the present observation that fisetin and probably genistein, these two agents knownto be inhibitors of protein kinase, affected angiogenesis and also by our previous finding that herbimycin A, a protein tyrosine kinase inhibitor, inhibits angiogenesis10). Alternatively, it might be possible that staurosporine modifies the differentiation of angiogenic endothelial cells, resulting in angiogenesis inhibition, since staurosporine modulates cell differentiation induced by various agents, retinoic acid and la,25-dihydroxyvitamin D317) and since our previous observations that retinoids and vitamin D3 analogs, both of which are well-known to modify cell differentiation, are potent angiogenesis inhibitors1 1>18). The antiangiogenic potency of staurosporine with an ID50 value of 71 pmol/egg was stronger than those of herbimycin A with an ID50 value of 260pmol/egg, la,25-dihydroxyvitamin D3 with an ID50 value of 340 pmol/egg and retinoic acid with an ID50 value of 330 pmol/egg10'l l!l8). Staurosporine appears to exhibit similar antiangiogenic activity as 22-oxa-la,25(OH)2D3 with an ID50 value of 96pmol/egg18) and has somewhat less an angiogenesis-inhibitory effect than the most potent angiogenesis inhibitor, a synthetic retinoid Ch 55 with an ID50 value of 24pmol/eggll). In this study staurosporine did not inhibit the migration of vascular endothelial cells. On the other hand Rosen et ah reported that staurosporine inhibited vascular endothelial cell migration19). This discrepancy might due to the difference in stimulators used for inducing cell migration; serum in our study and scatter factor (or TPA) in their experiment as a stimulator was used, respectively. Alternatively, it might result from the difference in the source of vascular endothelial cells used; our cells were derived from carotid and their cells from brain.
On the basis of the previous findings that staurosporine exhibits different biological and biochemical activities in various in vitro and in vivo systems20~27) and the present observation that it is also able to inhibit strongly angiogenesis in an in vivo system, we should discuss the specificity of staurosporine as an angiogenesis inhibitor. Taking all the findings together, it seems that staurosporine is a potent angiogenesis inhibitor although it dose not selectively affect angiogenesis. When estimated on an IC50 value available as to cell proliferation inhibition of staurosporine, although our vascular endothelial cells (IC50 = 0.9 nM) is more sensitive to the antibiotic than other cell types22'28'29), including Walker carcinoma cells (IC50 =40 nM), T-24 human bladder carcinoma cells (IC50 =29 nM), HL-60 promyelocytic leukemia cells (IC50= 130nM), bovine corneal endothelial cells (IC50=22nM) and mouse megakaryoblastic cells other. However, we should emphasize that the present observation is interesting that both the inhibition of endothelial cell proliferation and blood vessel formation in the CAM caused by staurosporine apparently occur at similar concentrations, although not conclusive, because local staurosporine concentration in CAMcould not be determined at present.
In summary, staurosporine, a potent inhibitor of protein kinases, has the ability to inhibit within a picomolar range of dose. This indicates possible role of certain protein kinase(s) during angiogenesis. In addition, the present study indicate that staurosporine is useful in elucidating a molecular mechanism of angiogenesis. Further study is in progress to determine which protein kinase(s) is a key role in angiogenesis induction. 
